News & Updates
Filter by Specialty:
Show Multimedia Only
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
28 Sep 2025
byStephen Padilla
Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
28 Sep 2025
Romosozumab improves bone health in osteoporotic women with diabetes
27 Sep 2025
byStephen Padilla
Treatment with romosozumab for 12 months, followed by 24 months of alendronate, results in significant improvements in lumbar spine areal bone mineral density (BMD) and tissue thickness-adjusted trabecular bone score (TBS) algorithm (TBSTT) compared with alendronate alone among postmenopausal women with osteoporosis and type 2 diabetes (T2D), reports a study.
